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Abstract
Background: Implantable cardioverter-defibrillator leads from Riata® family (St. Jude Me-
dical Inc., Sylmar, CA, USA) have been recently recalled by Food and Drug Administration 
for concerns of a unique type of “inside-out” insulation failure leading to conductor externa-
lization. The objective of this study was to evaluate the prevalence and predictors of conductor 
externalization in patients implanted with Riata 8 French (Fr) and 7 Fr leads.
Methods: Patients implanted with Riata® and Riata ST® who were actively followed up in 
our institution were scheduled for high resolution 3 view fluoroscopy and device interrogation 
including high voltage (HV) lead impedance testing. Fluoroscopic images were graded as pre-
sence of externalization or no externalization.
Results: Of the 90 patients who underwent screening fluoroscopy, majority had dual coil leads 
(62.5%) and median duration from the implant time to screening was 79.5 months. Twenty 
four (26.7%) patients exhibited evidence of lead externalization with 10 (41.6%) of these 
showing electrical abnormalities at the time of screening. No externalization was seen in the  
7 Fr leads. Pacing thresholds were significantly elevated in the externalized cohort compared to 
non-externalized group (1.42 ± 1.23 vs. 0.93 ± 0.53; p = 0.01). Time since lead implant and 
lead diameter emerged as significant predictors of lead externalization on univariate analysis 
with only lead diameter being significant on multivariate analysis (odds ratio 30.68; 4.95–∞, 
p = 0.001).
Conclusions: Prevalence of insulation failure exhibiting as conductor externalization is high 
(26.7%) among the large diameter 8 Fr Riata® leads with a significant proportion of patients 
manifesting electrical failure. High resolution 3 view fluoroscopy is a reasonable approach to 
screen for this unique type of insulation failure. (Cardiol J 2015; 22, 1: 57–67)
Key words: implantable cardioverter-defibrillators, Riata leads, fluoroscopy 
screening, externalization, electrical failure, lead recall
Introduction
Since the introduction of implantable cardio-
verter-defibrillator (ICD) for sudden cardiac death 
prevention, there have been a number of reported 
malfunctions related to lead durability or perfor-
mance [1]. Lead material and design play a crucial 
role in optimal performance of an ICD system and 
over the years, there have been several attempts 
to make thinner leads offering easier and better 
implantation profiles. Recently, leads from Riata® 
family (St. Jude Medical Inc., Sylmar, CA) have 
come under Food and Drug Administration (FDA) 
class I recall after cases of lead insulation failure 
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surfaced in various publications [2–4]. Specifically, 
the silicone insulation on the multi-lumen Riata® 
and Riata® ST leads has been noted to break in 
a unique “inside-out” fashion causing externali-
zation of the various internal conductors from the 
main lead body. Prior studies have reported various 
electrical abnormalities associated with lead exter-
nalization such as pacing impedance rise, increased 
capture threshold or inappropriate ICD shocks due 
to noise [2, 5]. Earlier studies have shown a low 
rate of lead insulation failure (< 1%) but these 
studies were limited due to the way insulation 
failure were analyzed (no consistent fluoroscopy) 
or shorter period of follow up [6, 7]. A recent large 
study by Hauser et al. [8] reported an alarming 
number of deaths in patients implanted with Ria-
ta® and Riata® ST leads primarily associated with 
failed defibrillation. A number of other reports have 
indicated that the actual prevalence of this unique 
“inside-out” abrasion defect is higher than that of 
previous reports, citing rates of insulation breach 
of around 20–33% when examined by a systema-
tic fluoroscopic approach [9–11]. So far no clear 
answers have been discovered as to what causes 
the lead insulation to break in this unique fashion 
thereby causing conductor externalization and only 
the duration of lead implant (dwell time) and lead 
size have emerged as the significant predictors of 
lead externalization in various studies.
This study was initiated to further define the 
prevalence of lead failures at our center and to 
investigate the predictors of lead externalization 
by performing systematic fluoroscopic screening.
Methods
Study population
All patients who received a single chamber, 
dual chamber, or biventricular ICD at our institu-
tion from January 2002 to December 2010 were 
screened from our central database software (Med-
tronic Paceart®) to identify individuals in whom 
a 7 and 8 French (Fr) transvenous Riata® family leads 
(models 1570, 1571, 1572, 1580, 1581, 1582, 1590, 
1591, 1592, 7000, 7001, 7002, 7010, 7040, 7041 and 
7042) were implanted. Of the total 271 patients 
who were implanted at our institution, 87 were 
found to be deceased, 3 had heart transplantation 
and 57 patients were followed at other institutions. 
We contacted 124 patients via telephone for study 
participation and informed them about the FDA re-
call. Ninety patients agreed to participate and were 
scheduled for voluntary screening fluoroscopy and 
simultaneous device interrogation. Data pertaining 
to baseline demographics, medical history and de-
vice/lead specifics were collected by chart review 
through the electronic medical record database. 
This protocol was approved by our institution re-
view board. The following clinical variables were 
analyzed: age, sex, device indication (primary vs. 
secondary prevention as well as underlying etio-
logy of cardiomyopathy), lead access technique 
(subclavian vs. axillary puncture), number of high 
voltage coils (single or dual), device type (single 
chamber, dual chamber or biventricular), lead size 
(7 Fr or 8 Fr), as well as the presence and seve-
rity of any detected tricuspid regurgitation after 
implant.
ICD interrogation
Device interrogation was performed to me-
asure sensing and capture threshold along with 
pace-sense impedance testing. High voltage (HV) 
integrity testing to determine HV lead impedance 
was also done at the time of interrogation. We did 
not perform HV impedance testing by delivering 
maximal output shock. These electrical parame-
ters were compared to the baseline values at the 
time of lead implant as ascertained by reviewing 
the operative notes in our hospital electronic 
record system. Both remote and in-clinic interro-
gation reports were also reviewed for any events 
suggestive of abnormal electrical parameters or 
delivered therapies prior to the screening period. 
Similar data up to 6 months post screening was 
also collected.
Fluoroscopy
Cine fluoroscopy at 15 frames per second was 
performed in our electrophysiology laboratory in 
3 views: anteroposterior, left anterior oblique (LAO) 
and right anterior oblique (RAO) around 30o each. 
Additional views were also obtained to bring out 
the maximal lead separation in cases where lead 
defects were noted. Frame by frame analysis was 
done and leads were followed from the lead tip 
in the ventricle to the can pocket. Prior available 
chest X-rays were also viewed at high magnification 
for cases where evidence of lead externalization 
was seen on fluoroscopy to retrospectively deter-
mine the earliest time when externalization was 
visualized. We also evaluated the presence of the 
lead curve in the right atrium before it enters the 
right ventricle (called RA/RV heel in this study) to 
assess if the curvature acts as the point of maxi-
mum stress causing insulation damage.
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Definition of lead failure
Lead externalization was defined as any visible 
defect where the inside conductor was clearly se-
parated from the main body of the lead. Cases were 
grouped as having evidence of lead externalization 
or no externalization. Patients with evidence of ab-
normal conductor spacing without overt separation 
from main lead body (early externalization) were 
analyzed in the externalization cohort. Abnormal 
electrical parameters were defined as (a) Change in 
HV lead impedance to < 25 Ω or > 200 Ω; (b) RV 
pace-sense lead impedance decrease to < 200 Ω 
or > 2000 Ω; (c) Presence of non-physiological 
signals on the intracardiac ventricular electrogram 
tracings; (d) Rise in capture threshold to > 2 V 
at 0.5 ms from baseline of < 1 V or rise to > 5 V; 
(e) Undersensing of the ventricular signal < 3.0 mV; 
(f) Inappropriate shocks were defined as those due 
to noise (in the absence of external interference or 
oversensing) detected on the leads. Inappropriate 
shocks due to supraventricular tachycardia and due 
to oversensing were excluded from our definition 
of inappropriate shocks. Episodes due to short RR 
intervals as a result of sensing of non-physiologic 
potentials leading to shocks were considered as 
inappropriate shocks.
Statistical techniques
Continuous variables are expressed as mean ± 
± standard deviation as assessed by the c2 test. 
Categorical parameters are presented as percen-
tages using Wilcoxon 2-sample test. Primary end 
point of our study was to determine the prevalence 
of lead externalization behavior among all Riata 
leads with secondary focus on electrical abnorma-
lities. A multivariate analysis was performed in 
a forward stepwise fashion to determine predictors 
of lead externalization. A two sided p-value of 
< 0.05 was considered statistically significant for 
the purpose of this study. All analyses were per-
formed using SAS® version 9.1 (SAS Institute Inc., 
Cary, NC, USA).
Results
Patient characteristics and ICD leads
Baseline characteristics and device/lead data 
is presented in Table 1. Ninety patients underwent 
concomitant fluoroscopy and device interroga-
tion with mean age of the cohort being 68.8 ± 
± 12.2 years at the time of interrogation. Mean 
left ventricular ejection fraction at the time of lead 
implantation was 25.6 ± 11.4%. Almost half of the 
patients in each group had underlying ischemic 
cardiomyopathy with most devices implanted 
for primary prevention of sudden cardiac death 
(84.4% of the total cohort). A majority of the leads 
belonged to the larger diameter 8 Fr series (60%). 
There were no significant differences in baseline 
characteristics between the two groups except for 
lead diameter with lead externalization seen only 
in the larger 8 Fr diameters leads (100% vs. 45%, 
p = 0.001).
Results of cine-fluoroscopic lead evaluation
Twenty four (26.7%) out of the total cohort 
of 90 study patients showed evidence of lead 
externalization on high-resolution fluoroscopy as 
exemplified in Figure 1. Only 1 (1.1%) case of early 
externalization was noted. Early externalization 
was defined as abnormal separation of internal 
conductors without overt separation from the main 
lead body. Of the patients with conductor exter-
nalization, 10 (41.6%) had a single chamber ICD, 
9 (37.5%) had a dual chamber ICD with remaining 
5 (20.8%) being biventricular ICD. Twenty one 
leads in the externalized groups were positioned 
in the right ventricle apex and 3 in the septal posi-
tion. A significant proportion of the leads (62.5%) 
were dual coil leads. The distribution of patients 
with lead externalization in relation to time since 
implant is depicted in Figure 2. The rate of exter-
nalization was 0/36 (0%) for leads with dwell time 
< 5.5 years as compared to 24/54 (44.4%) with 
dwell time > 5.5 years (p = 0.001). The majority 
of lead externalizations (75%) were seen in the RA 
where the lead bends to cross the tricuspid valve 
followed by the region proximal to the distal coil. 
Most of the leads showed externalization in both 
LAO and RAO views without requiring additional 
views. A significant proportion of the externaliza-
tions were noted among the 8 Fr single and dual 
coil Riata® leads corresponding to series no: 1582 
(6/24; 25%) and 1581 (10/24;42%), respectively 
as depicted in Figure 3. RA/RV heel was present 
almost equally amongst the two groups (83.3% vs. 
86.4%, p = 0.718).
ICD interrogation
When overall lead failure rate was considered, 
30% (27/90) of the leads showed evidence of lead 
externalization or electrical malfunction. Three of 
the 27 leads showed no externalization but rise in 
capture threshold to > 2 V at 0.5 ms. Ten (41.6%) of 
the 24 leads with evidence of fluoroscopic externa-
lization showed electrical abnormalities compared 
to 3/66 (4.5%) non-externalized leads (p = 0.001). 
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Table 2 shows the device electrical parameters at 
baseline (at the time of lead implantation) and at 
the time of screening fluoroscopy. Table 3 depicts 
the type of electrical abnormalities detected in 
externalized leads. Four out of 24 (16.6%) patients 
with externalized lead had pacing threshold > 2.0 V 
at the time of screening compared to 4/66 (6.0%) 
in the non-externalized cohort. Externalized leads 
showed higher ventricular pacing thresholds at the 
time of screening (1.42 ± 1.23 vs. 0.93 ± 0.53, 
p = 0.011) as compared to non-externalized leads 
with no statistically significant difference at the 
time of implantation. Also the mean threshold 
change between the two groups was significantly 
higher for the externalized leads (0.93 ± 1.36 vs. 
0.37 ± 0.58, p = 0.009). No significant difference 
was noted for pace-sense lead impedance or HV 
lead impendence between the two groups. When 
more than 30% decrease in R wave amplitude was 
looked at, we found no major differences.
Predictors of lead externalization
On univariate analysis, time since lead im-
plant and lead diameter emerged as the significant 
predictors of lead externalization. Duration of lead 
implant had an odds ratio of 1.07 for a 1-month pe-
riod with a 95% confidence interval of 1.03–1.10. 
When multivariate analysis was performed in 
a forward stepwise fashion, only the lead diameter 
came out as a significant predictor of lead exter-
nalization with an odds ratio of 30.68 (4.95–∞, 
p = 0.001). All other variable when adjusted for 
lead size became insignificant. Presence of dual 
coil, lead tip position, presence of RA/RV heel, 
tricuspid regurgitation severity did not predicted 
the outcome of interest.
Electrical behavior of externalized leads
Of the 24 externalized leads, 10 (41.6%) leads 
were found to have functional electrical abnorma-
lities of lead performance as outlined in Table 3. 
Table 1. Baseline characteristics of patients implanted with Riata® and Riata® ST leads.
Variable Total cohort
(n = 90)
Externalized 
lead cohort
(n = 24)
Non externalized 
cohort
(n = 66)
P
Demographics Age [years] 68.8 ± 12.2 69.2 ± 9.5 68.6 ± 13.0 0.999
Female 32.2 (29) 29.2 (7) 33.3 (22) 0.708
Black 43.3 (39) 41.7 (10) 44.0 (29) 0.714
Clinical parameters Hypertension 95.6 (86) 91.7 (22) 97.0 (64) 0.280
Diabetes 32.2 (29) 20.8 (5) 36.4 (24) 0.163
CKD 37.8 (34) 29.2 (7) 40.9 (27) 0.310
Atrial fibrillation 25.6 (23) 12.5 (3) 30.3 (20) 0.087
ICM 53.3 (48) 58.3 (14) 51.5 (34) 0.438
Moderate/severe TR 25.8 (23) 16.6 (4) 28.9 (19) 0.282
LVEF at implant 25.6 ± 11.4 25.4 ± 11.9 25.7 ± 11.3 0.923
Recent LVEF 35.0 ±13.7 34.9 ± 13.9 35.6 ± 14.1 0.828
LVEF change 9.6 ± 14.8 8.8 ± 12.3 9.9 ± 15.6 0.828
Device parameters Primary prevention 84.4 (76) 79.2 (19) 86.4 (57) 0.405
Single chamber 51.1 (46) 41.7 (10) 54.5 (36) 0.491
Dual chamber 28.9 (26) 37.5 (9) 25.8 (17)
Biventricular 20.0 (18) 20.8 (5) 19.7 (13)
Lead parameters RV-apex 66.6 (60) 87.5 (21) 91.0 (60) 0.634
≥ 2 RV leads 5.5 (5) 8.3 (2) 4.6 (3) 0.488
Left sided access 95.6 (86) 87.5 (21) 98.5 (65) 0.166
Active fixation 80.0 (72) 79.2 (19) 80.3 (53) 0.905
Dual coil 71.1 (64) 62.5 (15) 74.2 (49) 0.277
8 Fr leads 60.0 (54) 100.0 (24) 45.5 (30) 0.001
RA TV heel 85.6 (77) 83.3 (20) 86.4 (57) 0.718
Duration of lead  
implant [months]
70.1 ± 18.9 84.3 ± 13.3 65.0 ± 18.1 0.001
Categorical variables presented as percentage; CKD — chronic kidney disease, ICM — ischemic cardiomyopathy; TR — tricuspid regurgita-
tion; LVEF — left ventricular ejection faction; Recent LVEF — LVEF within 1 year of screening; RV — right ventricular; Fr — French;  
RA TV — right atrium tricuspid valve; 
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Figure 1. Cable externalization in three different cases as visualized by high resolution fluroscopy in right anterior obli-
que (RAO) and left anterior oblique (LAO) projections. Externalization noted at multiple levels in case 2. An example of 
grossly visible conductor externalization (arrow) (3B) seen on explantation along with its fluroscopy counterpart (3A).
1A
2A
3A
1B
3B
2B
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Most common presentation was rise in capture 
threshold followed by non-physiological noise on 
the leads. One patient in the non-externalized 
group with a Riata® 7040 dual coil 7 Fr lead was 
found to have sudden battery drain to < 2.2 V 
compared to a 3 month prior value of 2.67 V who 
underwent successful generator replacement with 
stable lead parameters.
Discussion
Our findings contribute to a growing pool of 
evidence regarding the high failure rates in Riata® 
family of leads. Our relatively high rate of lead ex-
ternalization (26.7%) is comparable to that found 
in other recent studies involving similar strategy 
of fluoroscopy of patients with Riata® and Riata® 
ST ICD leads. Study by Shen et al. [10] involving 
systematic fluoroscopy of 84 patients with 8 Fr 
and 7 Fr leads showed a prevalence of 27.4% of 
lead externalization. A similar strategy used by 
Liu et al. [9] in 245 asymptomatic patients im-
planted with Riata® and Riata® ST leads revealed 
a prevalence of 21.6%. Earlier studies reported 
a very low incidence of lead insulation damage at 
0.16% in 6,405 patients with a median follow-up 
of 24 months [7]. Another large series involving 
15,378 patients with a median follow-up period 
of 13.5 months reported insulation defects of the 
order of 0.21% [6]. These studies were limited by 
the way insulation defects were ascertained and no 
systematic fluoroscopy was used. Cine fluoroscopy 
with higher resolution capabilities is certainly more 
sensitive in detecting insulation breach compared 
to two view chest X-ray where the prevalence of 
lead externalization has been reported of the order 
of 11.5% to 24.3% [12, 13].
Lead externalization has been deemed as 
a time dependent process with multiple studies sho - 
wing lead dwell time to be an independent predictor 
of the unique “inside-out” insulation failure. In our 
study, patients with evidence of lead externali-
zation had longer duration of lead implant time 
(84.3 ± 13.3 months vs. 65.0 ± 18.1 months, p = 0.01). 
Median time from implantation to detection of lead 
externalization was 79.5 months. In the study by 
Liu et al. [9], 79.6% of the leads with definite ex-
ternalization had > 5 years dwell time and 18.8% 
had dwell time between 3 and 5 years at the time 
of screening. All leads in our externalized cohort 
had a dwell time > 5 years. When adjusted for lead 
diameter in multivariate analysis, lead dwell time 
was not an independent predictor of lead externa-
lization in our study. This result might suggest that 
the actual lead type rather than lead dwell time by 
itself is responsible for the externalization beha-
vior. This observation is further strengthened by 
Figure 3. Distribution of conductor externalization 
according to lead model type (8 Fr single coil models: 
1572, 1582; 7 Fr single coil models: 7002).
Figure 2. A. Distribution of externalized Riata leads by 
implant duration time; B. Distribution of externalized 
and non-externalized cohort in relation to implant du-
ration.
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Table 3. Summary of clinical/electrical presentation of patients with externalized conductors. 
No. Age Time since
implant
[months]
Impedance 
at screening
[Ω]
High voltage 
impedance 
[Ω]
Capture
threshold 
[V at 0.5 ms]
R wave 
amplitude
[mV]
Noise
Y/N
Unde-
-sensing
Increase
capture
threshold
IS
Y/N
1 82 76 353 31 1.2 8.3 N N N N
2 84 79 350 52 0.25 8.8 N N N N
3 73 96 300 37 0.625 11.9 N N N N
4 80 72 360 44 1 12 N N N N
5 74 69 420 47 0.5 12 N N N N
6 76 68 335 42 1 11.5 N N N N
7 70 113 589 75 0.75 20 Y N N N
8 67 84 405 33 1.25 11 N N N N
9 65 76 475 57 0.75 12 N N N N
10 59 83 540 60 0.5 9.8 Y N N N
11 71 73 720 47 6 12 N N Y N
12 75 85 430 53 2 7.7 N N N N
13 51 76 380 77 0.75 12.1 N N N N
14 75 111 290 46 1 11.7 N N N N
15 54 78 425 54 1.25 9.7 N N N N
16 49 84 380 51 1 1.8 N Y N N
17 66 70 365 49 1.5 10.4 N N N N
18 61 109 374 63 0.7 21 Y N N N
19 71 94 390 57 0.75 11.9 N N N N
20 74 78 1950 57 2.75 11.6 N N Y N
21 82 80 760 67 2.0 4.9 Y N N N
22 65 100 380 45 4 9 N N Y N
23 64 77 350 90 2.25 5.4 N N Y N
24 72 91 400 72 0.5 11.1 N N N N
Y — yes; N — no; IS — inappropriate shock
Table 2. Summary of various electrical parameters at the time of initial lead implant and at screening. 
Data expressed as mean ± standard deviation.
Variable Total cohort
(n = 90)
Externalized 
lead cohort
(n = 24)
Non externalized
cohort
(n = 66)
P
R wave amplitude [mV]
Baseline 13.5 ± 6.4 14.8 ± 5.0 13.1 ± 6.8 0.062
Screening 10.6 ± 3.5 10.8 ± 3.9 10.5 ± 3.3 0.590
Change –2.9 ± 6.2 –4.00 ± 5.1 –2.5 ± 6.5 0.114
> 30% R amplitude decrease 26.6 (24) 33.3 (8) 24.2 (16) 0.414
Pacing threshold [V at 0.5 ms]
Baseline 0.54 ± 0.22 0.50 ± 0.14 0.55± 0.24 0.652
Screening 1.06 ± 0.83 1.42 ± 1.23 0.93 ± 0.53 0.011
Change 0.52 ± 0.88 0.93 ± 1.36 0.37 ± 0.58 0.009
High voltage impedance [Ω]
Baseline 45.8 ± 12.6 47.0 ± 11.3 45.3 ± 13.0 0.379
Screening 52.9 ± 14.3 54.5 ± 15.0 52.5 ± 14.1 0.348
Change 7.3 ± 13.8 9.1 ± 13.7 6.7 ± 13.9 0.649
Right ventricular impedance [Ω]
Baseline 657.1 ± 176.5 666.2 ± 189.5 654.0 ± 173.1 0.704
Screening 472.6 ± 208.0 488.3 ± 332.9 466.7 ± 140.0 0.168
Change –187.2 ± 260.5 –172.5 ± 388.0 –192.4 ± 201.0 0.534
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description of Krebsbach et al. [2] case where they 
reported cable externalization as early as 4 months 
post implant in a lead extracted for concerns of 
microperforation. Schmutz et al. [12] reported 
4 cases with externalization visualized on prior 
coronary angiograms as early as 19 months post 
implant. When we looked at the available chest 
X-rays for patients in our externalized cohort, we 
found evidence of insulation defects as early as 
22 months in one of the patients.
Most of the leads in our study (75%) showed 
insulation break in the RA/tricuspid valve region 
as described previously in the study by Erkapic et 
al. [3]. This observation likely points to the fact 
that the tricuspid valve/low RA level where the 
lead takes a curve before entering the RV, repre-
sents the area of maximum stress which together 
with repetitive motion and contact with the valve 
during the cardiac cycle creates the right milieu 
for insulation failure.
Only the larger diameter 8 Fr leads exclusively 
demonstrated lead insulation failure of this unique 
type in our study. Our results differ markedly from 
other studies in that we did not find any case of 
lead externalization in smaller 7 Fr leads which 
comprised 40% of the total patient cohort. In 
a large study from Netherlands [14] involving 1,029 
patients, 29.8% (44/147) leads with externalization 
belonged to the 7 Fr group. In the manufacturer 
driven phase I study, 259 leads out of 718 were of 
7 Fr diameter and the overall prevalence of exter-
nalization was lower (9.3% vs. 24.0%, p < 0.001) 
compared to 8 Fr diameter leads [15]. Given that 
the 70XX series leads were introduced later than 
the 15XX series contributing to lesser implant 
duration times, an analysis accounting for lead 
implant time in the same study still showed lower 
prevalence of externalization in the 7 Fr series 
(9.4% vs. 17.9%, p = 0.02). St. Jude Medical attri-
butes these differences in externalization behavior 
among the smaller diameter leads to better lead 
design whereby the conductors are situated closer 
to the smaller central coil with similar thickness 
of silicone insulation [15]. The fact that we did 
not find any evidence of externalization in the 
7 Fr series could be due to small number of patients 
screened in our study.
Leads with extruded cable conductors had 
a significantly higher capture threshold at the 
time of screening in our study compared to non-
-externalized leads (1.42 ± 1.23 vs. 0.93 ± 0.53, 
p = 0.01). Even the change in capture threshold com-
pared to implant values was significant (p = 0.009). 
Similar finding was observed in the study by 
Steinberg et al. [13] where abnormal leads had 
higher pacing threshold (1.1 ± 0.8 vs. 0.9 ± 0.4 V, 
p = 0.02). We did not find any significant differen-
ces with other electrical parameters among the two 
groups. In the nationwide fluoroscopy screening 
series from Denmark involving 298 patients, only 
the pacing lead impedance was different among 
the normal and externalized group at the time of 
implant with no significant differences in any of 
the other electrical parameters at screening [15]. 
Data from a large cross sectional study from 
Canada surveying 4,358 leads revealed an ove-
rall 4.6% rate of electrical abnormalities, most 
common being elevated pacing thresholds and 
pacing lead impedance [16]. A multicenter stu-
dy by Abdelhadi et al. [17] also found higher 
electrical failure in 27% of the externalized lead 
cohort, suggesting leads with externalization 
are more likely to have electrical malfunction. 
These findings likely suggest that leads with 
externalization will likely manifest some form 
of electrical malfunction over time and as such 
require very close monitoring of electrical pa-
rameters and should prompt appropriate action, 
if significant electrical defects are detected. We 
did not observe significant differences in R wave 
amplitude decrease as has been seen in the study 
by Liu et al. [9] and Kubala et al. [18].
High voltage impedance values remained 
stable in both groups in our study which has been 
seen in almost all other published studies. We have 
reported a case of failed defibrillation in a patient 
who came to our attention when his device recor-
ded low (< 10 Ω) HV impedance during therapy 
delivery for a supraventricular tachycardia detected 
as ventricular tachycardia [19]. Hauser et al. [20] 
found 13 out of 22 cases of deaths related to Riata® 
and Riata ST® where HV impedance issues were 
detected. In their analysis of explanted leads from 
the Manufacturer and User Facility Device Defined 
Experience (MAUDE) database of 105 patients, 
almost a quarter (26.7%) leads had evidence of 
inside-out insulation defect under one or more of 
the HV shocking coils [20]. These observations 
are worrisome as the integrity and functionality of 
the HV system may not come into attention until 
delivery of therapy as no significant deviations are 
noted on routine surveillance. What is even more 
worrisome is the possibility of potential insulation 
failure under the shocking coil without externa-
lization anywhere else which is not visible with 
any imaging techniques. These findings highlight 
an important and complex issue regarding patient 
management, especially in those who have a device 
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for secondary prevention of sudden cardiac death 
as failure to deliver therapy could be catastrophic 
at the time of need.
To make the matter more complex, extraction 
of Riata® and Riata ST® leads poses unique challen-
ges with resultant higher procedural risks. Even 
though the extraction procedure was reported to 
be safe in a study by Patel et al. [21] where they 
extracted 20 dual coil leads with a mean dwell 
time of 48 ± 27 months, almost 90% of them 
required laser-powered tools and larger sheaths 
for extraction. This complexity arises from the 
lead design in Riata® and Riata® ST leads where the 
externalized conductors (attached to the distal edge 
of the proximal HV coil) when pulled during the 
extraction maneuver start to “bunch-up” in front of 
the sheath. This “snowplowing“ effect as described 
by Patel et al. [21] then requires larger sheaths to 
accommodate the conductors thus raising the com-
plications rates. Moreover, the HV coil has a round 
profile in the 8 Fr 15XX series leads compared to 
7 Fr leads where the profile is flat and backfilled 
with silicone material. This lack of backfill in the 
larger 8 Fr leads invites more tissue in-growth in 
the lead leading to difficulty during extraction.
Decision regarding abandoning the externa-
lized lead instead of extracting is very complex 
which involves careful consideration of each indi-
vidual patient factor such as age, presence of co-
-morbidities, pacemaker dependence, overall frailty 
and indication for the ICD. Addition of another ICD 
lead to an existing lead with extruded conductors 
can possibly interfere with the ICD lead function 
such as during delivery of HV shock due to possi-
bility of short circuiting thereby leading to failed 
defibrillation. In a large Veterans Affairs study by 
Sung et al. [22], defibrillation testing demonstrated 
a 10-J safety margin in 18 patients who had aban-
doned Riata® family leads and underwent addition 
on a new ICD lead. Also no electrical malfunctions 
due to lead-lead interaction were observed for an 
average follow-up of 18.2 months in the same study. 
It is to be noted that data regarding lead externa-
lization was not available in this particular study.
It is well known that medical grade silicone has 
high tensile strength, flexibility and bio-stability 
but low resistance to abrasion. A recent study 
from Kołodzińska et al. [23] has challenged the bio-
-stability of silicone by observing extensive mac-
rophage accumulation at the site of already abraded 
silicone using electron microscopic techniques. 
They also observed accelerated silicone degra-
dation in the presence of microorganisms such as 
Staphylococcus aureus species. These results raise 
an important issue with externalized Riata® family 
leads where the already abraded silicone insulation 
might serve an easy nidus for infective endocar-
ditis, should these patients develop blood stream 
infections. Externalized conductors have also been 
associated with thrombus formation as described 
in a recent case report by Ricciardi et al. [24] 
where they found a 3.5 cm × 1.5 cm thrombus at-
tached to the externalized segment of the lead with 
extensive fibrotic attachment to the tricuspid valve.
Limitations of the study
This is a single center study involving a mo-
dest number of patients. Exclusion of expired 
patients at the time of study possibly introduces 
a selection bias. We did not collect data on expi-
red patients or those who refused the screening. 
Also due to the retrospective analytic design of 
the study, the actual time from lead implantation 
to insulation failure cannot be determined which 
remains the biggest limitation in all other published 
studies as well. None of the patients included had 
Riata ST Optim® leads, thereby limiting our ana-
lysis to non-optim® coated Riata leads.
Clinical implications
Insulation failure especially the inside-out 
variety, in patients implanted with Riata® and Riata 
ST® ICD leads is emerging as a growing problem. 
Clearly the prevalence of lead externalization is 
high in the range of > 20% as shown by ours and 
recent other studies. Most of the visual lead defects 
are electrically silent on a routine interrogation but 
stakes are high as demonstrated by failed device 
therapy delivery for arrhythmias and by the deaths 
reported in the study from Hauser et al. [8]. Our 
study showed that over time, electrical parameters 
do show a trend towards higher pacing thresholds 
in leads with extruded conductors, however the 
timing and ultimate outcome of these changes 
remain unknown and at the present can’t be used 
to dictate clinical practice. Currently published 
literature on Riata® family of leads has led to 
more questions than answers. There are no clear 
guidelines as to when to perform fluoroscopy and 
how often, whether to perform noninvasive pro-
grammed stimulation testing and when to extract 
leads with externalized conductors. We recommend 
close monitoring of patients with 3-monthly office 
or remote monitoring and paying special attention 
to small changes in electrical parameters. We 
agree with the manufacturer recommended lead 
monitoring to use an unused electrogram channel 
to monitor for HV lead noise, program upper and 
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lower limits for pacing lead impedance to 1000 Ω 
and 200 Ω, respectively, use Secure SenseTM RV 
noise discriminator algorithm in devices where 
available. Also it has been proposed to change 
the detection criteria for ventricular fibrillation to 
increase the detection intervals to 30 to avoid brief 
episodes of noise being detected as tachycardia 
episode. Direct alert notifications via Merlin.net® 
patient care network should be set to “Urgent” 
or “Standard” modes whenever lead impedance, 
noise or noise reversion issues are detected. 
As of present, the FDA has mandated routine 
imaging either with fluoroscopy or 2-view chest 
X-ray to assess lead externalization in all patients 
with Riata® family leads [25]. Decision regarding 
abandoning vs. extracting a Riata lead needs to be 
individualized based on patient factors, indication 
for ICD, need for pacing and operator experience. 
Given the complexities associated with extracting 
leads with extruded cables, it seems reasonable to 
extract only those leads with electrical malfunction 
and closely following the ones with externalization 
and normal electrical parameters, or normal fluo-
roscopic appearance. There is no consensus as of 
yet to determine the frequency of imaging patients 
who have no evidence of conductor externalization 
on initial fluoroscopy. We think it is reasonable to 
continue with systematic imaging at reasonable 
intervals in patients showing marked externali-
zation and normal electrical testing. Large-scale 
prospective studies such as one being conducted by 
St. Jude Medical might help to further define this 
growing problem and to determine optimal mana-
gement strategy for these high-risk patients [26].
Conclusions
Insulation failure among the Riata® large dia-
meter ICD leads as determined by high resolution 
3 view fluoroscopy is significant (~27%) with rise 
in pacing threshold over time. Patients may present 
with loss of HV lead integrity/function at the time 
of need during life threatening ventricular arrhyth-
mias with potential fatal consequences. Systematic 
lead fluoroscopy as recommend by FDA and regular 
device interrogation with close attention to small 
changes in electrical parameters seems to be most 
prudent approach at this juncture in time for this 
high risk patient population.
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